KKR allots 60% of BridgeBio stock sales to five firms (BBIO)
· seekingalpha.com
KKR (KKR) allocates nearly 60% of BridgeBio Pharma's (BBIO) secondary offering to the five biggest investors. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...